Immunotherapy with Allergen Peptides
Author:
Open Access
- 15 June 2007
- journal article
- Published by Springer Nature in Allergy, Asthma & Clinical Immunology
- Vol. 3 (2) , 53-9
Abstract
Specific allergen immunotherapy (SIT) is disease-modifying and efficacious. However, the use of whole allergen preparations is associated with frequent allergic adverse events during treatment. Many novel approaches are being designed to reduce the allergenicity of immunotherapy preparations whilst maintaining immunogenicity. One approach is the use of short synthetic peptides which representing dominant T cell epitopes of the allergen. Short peptides exhibit markedly reduced capacity to cross link IgE and activate mast cells and basophils, due to lack of tertiary structure. Murine pre-clinical studies have established the feasibility of this approach and clinical studies are currently in progress in both allergic and autoimmune diseases.Keywords
This publication has 58 references indexed in Scilit:
- Absence of T-regulatory cell expression and function in atopic dermatitis skinJournal of Allergy and Clinical Immunology, 2006
- T Cell Epitope Immunotherapy Induces a CD4+ T Cell Population with Regulatory ActivityPLOS Medicine, 2005
- Fel d 1‐derived T cell peptide therapy induces recruitment of CD4+CD25+; CD4+ interferon‐γ+ T helper type 1 cells to sites of allergen‐induced late‐phase skin reactions in cat‐allergic subjectsClinical & Experimental Allergy, 2005
- Cat allergen peptide immunotherapy reduces CD4+ T cell responses to cat allergen but does not alter suppression by CD4+ CD25+ T cells: a double‐blind placebo‐controlled studyAllergy, 2004
- IL‐10 and TGF‐β cooperate in the regulatory T cell response to mucosal allergens in normal immunity and specific immunotherapyEuropean Journal of Immunology, 2003
- Immunotherapy with Fel d 1 peptides decreases IL-4 release by peripheral blood T cells of patients allergic to catsJournal of Allergy and Clinical Immunology, 1998
- Effects of peptide therapy on ex vivo T-cell responsesJournal of Allergy and Clinical Immunology, 1998
- Antibody responses to bee melittin (Api m 4) and hornet antigen 5 (Dol m 5) in mice treated with the dominant T-cell epitope peptides☆☆☆★★★Journal of Allergy and Clinical Immunology, 1998
- Mucosal tolerance and suppression of collagen-induced arthritis (CIA) induced by nasal inhalation of synthetic peptide 184-198 of bovine type II collagen (CII) expressing a dominant T cell epitopeClinical and Experimental Immunology, 1996
- T Cell Deletion in High Antigen Dose Therapy of Autoimmune EncephalomyelitisScience, 1994